Effect	O
of	O
Genotype	O
and	O
Previous	O
GH	O
Treatment	O
on	O
Adiposity	O
in	O
Adults	O
With	O
Prader	B:C0032897
-	I:C0032897
Willi	I:C0032897
Syndrome	I:C0032897
.	O

Adults	O
with	O
Prader	B:C0032897
-	I:C0032897
Willi	I:C0032897
syndrome	I:C0032897
(	O
Prader	B:C0032897
-	I:C0032897
Willi	I:C0032897
syndrome	I:C0032897
)	O
have	O
an	O
increased	O
proportion	O
of	O
sc	B:C0222331
fat	I:C0222331
mass	O
compared	O
with	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
(	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
)	O
-	O
matched	O
controls	O
,	O
but	O
whether	O
the	O
genotype	O
influences	O
body	O
composition	O
and	O
metabolic	B:C3853758
profile	I:C3853758
remains	O
controversial	O
.	O

To	O
assess	O
body	O
composition	O
and	O
metabolic	B:C1864620
features	I:C1864620
in	O
adults	O
with	O
Prader	B:C0032897
-	I:C0032897
Willi	I:C0032897
syndrome	I:C0032897
,	O
according	O
to	O
genetic	O
subtype	O
.	O

Main	O
Outcomes	O
and	O
Measures	O
:	O
Body	O
composition	O
(	O
Dual	B:C1510486
Energy	I:C1510486
X-	I:C1510486
ray	I:C1510486
Absorptiometry	I:C1510486
)	O
and	O
metabolic	B:C0243095
parameters	I:C0243095
were	O
compared	O
in	O
Prader	B:C0032897
-	I:C0032897
Willi	I:C0032897
syndrome	I:C0032897
adults	O
(	O
mean	O
age	O
,	O
25.5	O
±	O
8.9	O
y	O
)	O
with	O
deletion	B:C0017260
(	O
n	O
=	O
47	O
)	O
or	O
uniparental	B:C0949628
disomy	I:C0949628
(	O
uniparental	B:C0949628
disomy	I:C0949628
)	O
(	O
n	O
=	O
26	O
)	O
,	O
taking	O
into	O
account	O
GH	O
treatment	O
in	O
childhood	O
and	O
/	O
or	O
adolescence	O
.	O

In	O
subgroups	O
,	O
adipocyte	O
size	O
,	O
fasting	B:C0015663
total	B:C3813179
ghrelin	I:C3813179
levels	I:C3813179
,	O
and	O
resting	B:C0429629
energy	I:C0429629
expenditure	I:C0429629
were	O
measured	O
,	O
and	O
hyperphagia	B:C0020505
was	O
assessed	O
by	O
the	O
Dykens	B:C0034394
Hyperphagia	I:C0034394
Questionnaire	I:C0034394
.	O

In	O
the	O
whole	O
sample	O
,	O
the	O
deletion	B:C1257890
group	I:C1257890
had	O
a	O
higher	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
compared	O
with	O
uniparental	B:C0949628
disomy	I:C0949628
(	O
40.9	O
±	O
11.5	O
vs	O
34.6	O
±	O
9.6	O
kg	O
/	O
m	O
(	O
2	O
)	O
,	O
P	O
=	O
.02	O
)	O
,	O
but	O
there	O
was	O
no	O
difference	O
between	O
groups	O
in	O
percent	B:C0518026
body	I:C0518026
fat	I:C0518026
,	O
metabolic	B:C3853758
profile	I:C3853758
,	O
adipocyte	B:C0206131
size	O
,	O
resting	B:C0429629
energy	I:C0429629
expenditure	I:C0429629
,	O
hyperphagia	B:C0020505
score	O
,	O
or	O
ghrelin	B:C3813179
levels	I:C3813179
.	O

In	O
subjects	B:C0178693
previously	O
treated	B:C0332293
with	I:C0332293
GH	B:C0037663
,	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
was	O
not	O
different	O
between	O
uniparental	B:C0949628
disomy	I:C0949628
and	O
deletion	B:C1257890
groups	I:C1257890
(	O
33.0	O
±	O
9.7	O
vs	O
33.5	O
±	O
11.1	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O

In	O
addition	O
,	O
previous	O
GH	O
treatment	O
was	O
associated	O
with	O
decreased	O
percent	B:C0518026
body	I:C0518026
fat	I:C0518026
and	O
adipocyte	B:C0206131
volume	O
only	O
in	O
the	O
deletion	B:C1257890
group	I:C1257890
.	O

A	O
deletion	O
genotype	O
in	O
adults	O
with	O
Prader	B:C0032897
-	I:C0032897
Willi	I:C0032897
syndrome	I:C0032897
is	O
associated	O
with	O
increased	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
.	O

GH	O
treatment	O
in	O
childhood	O
and	O
/	O
or	O
adolescence	O
limits	O
this	O
deleterious	O
phenotypic	B:C4021819
effect	I:C4021819
with	O
improved	O
adiposity	O
markers	B:C0017393
.	O

This	O
study	B:C2603343
suggests	O
relationships	O
between	O
the	O
molecular	O
phenotype	O
of	O
Prader	B:C0032897
-	I:C0032897
Willi	I:C0032897
syndrome	I:C0032897
and	O
adipose	B:C0001527
tissue	I:C0001527
development	O
as	O
well	O
as	O
sensitivity	O
to	O
GH	B:C0037663
.	O

